Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane

J Gastroenterol Hepatol. 2006 Dec;21(12):1821-5. doi: 10.1111/j.1440-1746.2006.04420.x.

Abstract

Background: Oxidative stress plays an important role in the pathogenesis of chronic liver diseases. The plasma level of 8-isoprostane, a product of lipid peroxidation, is a marker of oxidative stress in vivo. The aim of the present study was to clarify whether the degree of lipid peroxidation, as measured by the plasma level of 8-isoprostane, influences the progression of chronic liver diseases and hepatocarcinogenesis.

Methods: Plasma 8-isoprostane levels were investigated in 14 patients with non-alcoholic fatty liver disease (NAFLD), 75 with chronic hepatitis C (CH-C), 14 with cured CH-C, 14 with HCV-positive hepatocellular carcinoma (HCC-C) and 38 healthy volunteers. 8-Isoprostane was measured by enzyme immunoassay after affinity column purification.

Results: Plasma 8-isoprostane was significantly elevated in NAFLD (11.9 [3.8-56.8] pg/mL), CH-C (10.1 [4.2-134.5] pg/mL) as compared to controls (6.3 [3.6-11.1] pg/mL). Plasma 8-isoprostane values were positively correlated with body mass index in NAFLD (P < 0.05) and with total cholesterol in cured CH-C (P < 0.01). 8-Isoprostane levels were not significantly related to sex, age, biochemical data or iron metabolism markers in all liver diseases. In addition, after the administration of peg-interferon, the values of 8-isoprostane improved in almost all patients, reaching values of healthy subjects.

Conclusions: 8-Isoprostane values are elevated in patients with NAFLD and CH-C as compared to healthy controls. Oxidative stress caused by increased lipid peroxidation is involved in the pathogenesis of NAFLD and CH-C.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • Dinoprost / analogs & derivatives*
  • Dinoprost / blood
  • Disease Progression
  • Drug Carriers
  • Fatty Liver / blood*
  • Fatty Liver / pathology
  • Female
  • Hepatitis C, Chronic / blood*
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / pathology
  • Humans
  • Immunoenzyme Techniques
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Lipid Peroxidation / physiology*
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use
  • Prognosis
  • Recombinant Proteins

Substances

  • Antiviral Agents
  • Biomarkers
  • Drug Carriers
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • 8-epi-prostaglandin F2alpha
  • Polyethylene Glycols
  • Dinoprost
  • peginterferon alfa-2a